Literature DB >> 15486871

Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings.

Francesco Locatelli1, Ronald L Pisoni, Tadao Akizawa, José M Cruz, Peter B DeOreo, Norbert H Lameire, Philip J Held.   

Abstract

BACKGROUND: After recombinant human erythropoietin was introduced into routine nephrologic practice, specific clinical guidelines were developed to optimize the quality of anemia management for patients with chronic kidney disease.
METHODS: The Dialysis Outcomes and Practice Patterns Study (DOPPS), an international investigation providing patient- and facility-level data on hemodialysis practice, was developed to provide information on various aspects of current practices in hemodialysis management, including treatment of renal anemia.
RESULTS: Hemoglobin concentration is strongly associated with both morbidity and mortality in hemodialysis patients. Although some improvements can be documented in anemia management practices in the years after the publication of international guidelines, wide variations in anemia management are still observed among countries.
CONCLUSION: Many efforts are still needed to allow a greater proportion of patients to reach the recommended hemoglobin concentrations. Significantly improved outcomes may therefore be expected by a more widespread reaching of the recommended hemoglobin levels. The results of the DOPPS point to the difficulties in implementing clinical guidelines in the everyday management of individual patients. In specific circumstances, a well-designed observational study may offer credible information and serve as a basic instrument for monitoring the implementation of clinical guidelines in typical clinical practice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486871     DOI: 10.1053/j.ajkd.2004.08.008

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  24 in total

Review 1.  Characteristics of the clinical practice patterns of hemodialysis in Japan in consideration of DOPPS and the NKF/DOQI guidelines.

Authors:  Satoru Kuriyama
Journal:  Clin Exp Nephrol       Date:  2008-01-09       Impact factor: 2.801

Review 2.  Development of quality indicators for care of chronic kidney disease in the primary care setting using electronic health data: a RAND-modified Delphi method.

Authors:  Shingo Fukuma; Sayaka Shimizu; Kakuya Niihata; Ken-Ei Sada; Motoko Yanagita; Tsuguru Hatta; Masaomi Nangaku; Ritsuko Katafuchi; Yoshiro Fujita; Junji Koizumi; Shunzo Koizumi; Kenjiro Kimura; Shunichi Fukuhara; Yugo Shibagaki
Journal:  Clin Exp Nephrol       Date:  2016-05-04       Impact factor: 2.801

3.  Anaemia in diabetic patients with chronic kidney disease--prevalence and predictors.

Authors:  S Al-Khoury; B Afzali; N Shah; A Covic; S Thomas; D J Goldsmith
Journal:  Diabetologia       Date:  2006-04-12       Impact factor: 10.122

4.  The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.

Authors:  Junichi Ishigami; Tsuyoshi Onishi; Satomi Shikuma; Wataru Akita; Yoshihiro Mori; Tomoki Asai; Michio Kuwahara; Sei Sasaki; Yusuke Tsukamoto
Journal:  Clin Exp Nephrol       Date:  2012-07-03       Impact factor: 2.801

5.  Effect of erythropoiesis-stimulating agents on hemoglobin level, fatigue and hospitalization rate in renal palliative care patients.

Authors:  Kwok-Ying Chan; Cho-Wing Li; Hilda Wong; Terence Yip; Mau-Kwong Sham; Hon-Wai Cheng; Kay-Cheong Teo; Wang-Chun Kwok; Tak-Mao Chan
Journal:  Int Urol Nephrol       Date:  2014-02-14       Impact factor: 2.370

6.  Factors associated with health-related quality of life among hemodialysis patients in the DOPPS.

Authors:  Antonio Alberto Lopes; Jennifer L Bragg-Gresham; David A Goodkin; Shunichi Fukuhara; Donna L Mapes; Eric W Young; Brenda W Gillespie; Tadao Akizawa; Roger N Greenwood; Vittorio E Andreucci; Takashi Akiba; Philip J Held; Friedrich K Port
Journal:  Qual Life Res       Date:  2007-02-08       Impact factor: 4.147

7.  Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis.

Authors:  Elani Streja; Csaba P Kovesdy; Sander Greenland; Joel D Kopple; Charles J McAllister; Allen R Nissenson; Kamyar Kalantar-Zadeh
Journal:  Am J Kidney Dis       Date:  2008-08-29       Impact factor: 8.860

8.  Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study.

Authors:  Rieko Eriguchi; Masatomo Taniguchi; Toshiharu Ninomiya; Hideki Hirakata; Satoru Fujimi; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  J Nephrol       Date:  2014-07-31       Impact factor: 3.902

Review 9.  The role of iron supplementation during epoietin treatment for cancer-related anemia.

Authors:  M Hedenus; G Birgegård
Journal:  Med Oncol       Date:  2008-05-13       Impact factor: 3.064

10.  Low hemoglobin levels and an increased risk of psoriasis in patients with chronic kidney disease.

Authors:  Si-Hyung Lee; Miri Kim; Kyung-Do Han; Ji Hyun Lee
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.